Are you Dr. Wikler?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
8039 Danny Boy Road
San Diego, CA 92127Phone+1 858-759-3456
Summary
- Dr. Matthew Wikler, MD is an infectious disease specialist in San Diego, California. He is currently licensed to practice medicine in California and Pennsylvania.
Education & Training
University of Pennsylvania Health SystemFellowship, Infectious Disease, 1978 - 1980
Abington Memorial HospitalResidency, Internal Medicine, 1975 - 1978
Lewis Katz School of Medicine at Temple UniversityClass of 1975
Certifications & Licensure
CA State Medical License 2008 - 2025
PA State Medical License 1976 - 2024
Publications & Presentations
PubMed
- 161 citationsSingle-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority...G. Ralph Corey, Samantha Good, Hai Jiang, Greg Moeck, Matthew A. Wikler
Clinical Infectious Diseases. 2015-01-15 - 15 citationsSingle intravenous dose of oritavancin for treatment of acute skin and skin structure infections caused by gram-positive bacteria: Summary of safety analysis from the ...G. R. Corey, Jeffery Loutit, Greg Moeck, M.W. Wikler, Michael N. Dudley
Antimicrobial Agents and Chemotherapy. 2018-03-27 - 26 citationsPooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large ...G. Ralph Corey, Francis F. Arhin, Matthew A. Wikler, Daniel F. Sahm, Barry N. Kreiswirth
International Journal of Antimicrobial Agents. 2016-11-01
Press Mentions
The Economic Burden of Non–Influenza-Related Viral Respiratory Tract Infection in the United StatesOctober 20th, 2016
